Iron Chelators in the Management of Autoimmune-Induced Alopecia: A Focus on Hypoxia-Inducible Factor 1 Modulation and Hair Restoration

March 2025 in “ Journal of Clinical Medicine ”

Andrea Pagani, Dominik Thor, Adriana C. Panayi, S. Klein, Sebastian Geis, Leonard Knoedler, Samuel Knoedler, Filippo Andrea Giovanni Perozzo, Giuseppe Sofo, Rafael Loucas, Lukas Prantl, Dominik Duscher

iron chelators deferoxamine deferiprone hypoxia-inducible factor 1-alpha HIF-1α vascularization cellular proliferation hair follicles alopecia oxidative damage inflammatory responses Janus kinase inhibitors JAK inhibitors DFO DFP

Studysummary This study highlighted the potential of iron chelators, deferoxamine and deferiprone, to improve hair density, thickness, and elasticity and reduce hair loss by up to 66.8% over six months in individuals with autoimmune alopecia, suggesting they may offer a promising therapeutic option.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on mdpi.com →

Discuss this study in the Community →

Research cited in this study

6 / 6 results

research Psychological Stress-Induced Pathogenesis of Alopecia Areata: Autoimmune and Apoptotic Pathways

3 citations , July 2023 in “International journal of molecular sciences”

This review discusses the association between emotional stress-related neuropeptides and the pathogenesis of alopecia areata, reporting no new experimental findings.

research Janus Kinase Inhibitors For Alopecia Areata

12 citations , June 2023 in “JAMA network open”

In this study of seven randomized clinical trials, JAK inhibitors were associated with improved hair regrowth outcomes in alopecia areata patients compared to placebo, with oral administration being more effective than external application, though longer trials are needed to confirm safety and effectiveness.

research A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in a Blinded Clinical Trial

1 citations , January 2023 in “Journal of Clinical Medicine”

This study reported that Tomorrowlabs HIF strengthening factor [HSF] hair restoration technology significantly improved hair thickness, density, shine, and elasticity, while reducing hair loss by an average of 66.8% and enhancing hair growth by up to 32.5% in subjects with androgenic alopecia over nine months.

research Prolonged Drug-Induced Hypersensitivity Syndrome/DRESS With Alopecia Areata and Autoimmune Thyroiditis

2 citations , August 2022 in “Federal Practitioner”

This case report describes a patient with lamotrigine-associated drug-induced hypersensitivity syndrome requiring prolonged and complex treatment, with observed complications including extensive alopecia areata and autoimmune thyroiditis.

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

research The JAK/STAT Signaling Pathway: From Bench to Clinic

489 citations , November 2021 in “Signal Transduction and Targeted Therapy”

This review discusses the composition, activation, and regulation of the JAK/STAT pathway and highlights its role and inhibitors in various diseases, but reports no new experimental results.